The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors and, although there is extensive new information on the etiology and pathogenesis of PD that may advance its treatment, new syntheses of this information are needed. The first part of this two-part, state-of-the-art review by leaders in Parkinson research critically examines the field to identify where new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part I include the definition of the disease, neuropathologic contributions, and epidemiologic, environmental, and demographic issues. The definition of idiopathic Parkinson disease (PD) remains controversial. Classically, it includes a characteristic motor phenotype (1) and a distinctive neuropathology and substantial loss of dopaminergic neurons from the substantia nigra associated with the presence of α-synuclein-positive inclusions in the cell body (Lewy bodies) and processes (Lewy neurites) of specific neurons of the brainstem. Some genetically determined Parkinson syndromes resemble, sometimes closely, idiopathic PD, but differ from it neuropathologically, sometimes substantially. In particular, a number of juvenile-onset autosomal recessive cases of familial Parkinson syndrome do not have α-synuclein lesions (2), contrasting with the autosomal dominant forms of the disease which often have unusual types of lesions (3-5). The recently identified leucine-rich repeat kinase 2 (LRRK2, Park-8) mutations produce variable pathologic phenotypes. Although the most common is Lewy body disease, nigral degeneration with ubiquitin inclusions or, in a few cases, even pathologic changes more typical of frontotemporal lobar degeneration or progressive supranuclear palsy have been described in patients with LRRK2 mutations (6). Two recent reports insist on the high prevalence of Lewy bodies in the LRRK2 mutations (7) but also describe a family with tau pathology (8). Neuropathology has revealed the considerable frequency with which idiopathic PD is associated with other degenerative conditions, notably Alzheimer disease, particularly in advanced age, even though the clinical consequences of multiple pathologies remain poorly defined. Moreover, an association with genetic variants that increase tau transcription occurs in all forms of Lewy body diseases (sporadic and familial), providing additional support for the involvement of tau in the pathogenic process (9, 10). Unfortunately, the cellular mechanisms by which this or other potential detrimental processes interact to produce the features of any form of PD remain purely speculative. Other synucleinopathies (disorders with α-synuclein aggregates) include dementia with Lewy bodies (DLB), multiple system atrophy in which α-synuclein constitutes characteristic inclusions, predominantly in oligodendrocyte cell bodies (11), and neurodegeneration with brain iron accumulation in which α-synuclein accumulates in axonal spheroids (12). The recognition of such varied disorders associated with abnormal α-synuclein aggregation in multiple cell types and cell compartments has broad implications for the etiopathogenesis of this group of disorders, suggesting that the selective disruption of diverse intracellular events utilizing α-synuclein leads to distinctive anatomical and cellular patterns of pathology. In particular, some patients with DLB have patterns of α-synuclein deposition identical to those seen in idiopathic PD but have no parkinsonism (13, 14). Moreover, as olfactory dysfunction, constipation, rapid eye movement sleep behavior disorder, and depression may precede or present commonly in early PD, they are proposed to be prodromic signs of PD (15). These symptoms correlate well with the deposition of α-synuclein in Braak stages 1 (olfactory bulb and peripheral and central medullary autonomic neurons) and 2 (locus ceruleus and pontine tegmentum), which are proposed to precede the clinical symptoms of PD (stage 3 with α-synuclein deposition in the substantia nigra) (16). Should the definition of PD rely on clinical (the extrapyramidal syndrome), pathologic (the α-synuclein deposition), or genetic data? When the full spectrum of clinical PD is present, there is a high probability of finding a devastating loss of dopamine neurons (17) with α-synuclein accumulation. Moreover, the loss of nigral neurons is correlated with the severity of akinesia and rigidity (18). However, the accumulation of α-synuclein may be absent in patients with genetically determined clinical PD. Mild parkinsonian symptoms in the elderly may also relate to the loss of dopamine neurons in the absence of α-synuclein deposition (19). In most if not all of these α-synuclein-negative cases, clinical PD is determined by lesions of the nigrostriatal
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Self-citationA meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818 · cited 2×
“Almost all studies have confirmed a lower incidence of PDamongsubjectswith ahistoryof smoking (69).”
Background
Cited by
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citationNeuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Metadata
- Authors
- Litvan, I., Halliday, G., Hallett, M., Goetz, C. G., Rocca, W., Duyckaerts, C., Ben-Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M.-F., Langston, W. J., Di Monte, D. A., Gasser, T., Hagg, T., Hardy, J., Jenner, P., Melamed, E., Myers, R. H., Parker, D., & Price, D. L.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04
- Volume
- 66
- Issue
- 4
- Pages
- 251-257
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1986977913
- Cited by
- 125
- References
- 20
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. https://app.cochat.ai/papers/10.1097/nen.0b013e3180415e42
- The paper
- Litvan, I., Halliday, G., Hallett, M., Goetz, C. G., Rocca, W., Duyckaerts, C., Ben-Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M.-F., Langston, W. J., Di Monte, D. A., Gasser, T., Hagg, T., Hardy, J., Jenner, P., Melamed, E., Myers, R. H., Parker, D., & Price, D. L. (2007). The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e3180415e42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.